innovation for industry
Europe | Health ＆ life sciences
BIOactive implantable CApsule for PANcreatic islet immunosuppression free therapy. 463 million people suffer from diabetes, an incurable pandemic caused by the pancreas not producing enough insulin. The aim of the BIOCAPAN project was to develop innovative cell therapy based on grafting encapsulated human insulin secreting cells.
New biomaterials were identified for inclusion in final bioactive capsule composition; these were optimised and tested in vitro and in vivo. This resulted in:
Demonstration of the positive role of mesenchymal stem cells (MSCs) and tripeptides arginine- glycine-aspartic acid conjugated to sodium alginate (RGD-alginate) on rat islet viability and functionality through co-culture experiments
Optimised production of GMP ultra pure Extra Cellular Matrix (ECM) mimicking the pancreatic islet microenvironment. Tests in vitro shown close biocompatibility and improvement in islet viability and functionality
Development of a zwitterionic (ZW) chitosan for coating microcapsules and preventing fibrosis. ZW chitosan was shown to be biocompatible without affecting capsule porosity. Initial in vivo assays proved that ZW coating reduced macrophages in the capsule periphery.
More information on Website
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.